although
berberin
alkaloid
ba
report
broadspectrum
antibacteri
antivir
activ
interact
among
ba
elucid
present
studi
methicillinresist
staphylococcu
aureu
mrsa
chosen
model
organ
modifi
broth
microdilut
appli
determin
fluoresc
absorpt
valu
calcul
antimrsa
activ
ba
initi
four
step
seek
optim
combin
ba
determin
antimrsa
activ
singl
ba
investig
twocompon
combin
clarifi
interact
among
ba
checkerboard
assay
investig
multicompon
combin
determin
optim
ratio
quadrat
rotationorthogon
combin
design
vivo
vitro
valid
optim
combin
result
show
interact
among
ba
relat
concentr
synerget
combin
includ
berberin
epiberberin
jatrorrhizin
palmatin
jatrorrhizin
coptisin
antagonist
combin
includ
coptisin
epiberberin
optim
combin
berberin
coptisin
jatrorrhizin
palmatin
epiberberin
potenc
optim
combin
cyclophosphamideimmunocompromis
mous
model
better
natur
combin
herb
contain
ba
seek
multicompon
drug
tradit
medicin
one
research
direct
treat
mrsa
infect
rhizoma
coptidi
use
two
thousand
year
china
known
antibiot
tradit
chines
medicin
although
mani
studi
conduct
antimicrobi
activ
berberin
alkaloid
ba
past
decad
paid
attent
interact
among
ba
know
ba
activ
compon
sever
tradit
medicin
rhizoma
coptidi
phellodendri
chinensi
berberidi
radix
awar
interact
among
ba
great
valu
exploit
multicompon
drug
present
studi
methicillinresist
staphylococcu
aureu
mrsa
chosen
model
organ
studi
interact
among
ba
mrsa
one
pathogen
clinic
separ
strain
lead
high
morbid
mortal
due
multidrugresist
genotyp
mrsa
sensit
lactam
antibiot
also
resist
aminoglycosid
fluoroquinolon
chloramphenicol
macrolid
glycopeptid
vancomycin
teicoplanin
singledrug
treatment
modal
slow
bottl
neck
altern
multicompon
natur
medicin
might
one
direct
futur
antibacteri
drug
develop
expect
clarifi
synerget
antagonist
action
seek
optim
combin
ba
manifest
strongest
antimrsa
activ
initi
four
step
seek
optim
combin
ba
determin
antimrsa
singl
ba
investig
twocompon
combin
clarifi
interact
among
ba
checkerboard
assay
investig
multicompon
combin
determin
optim
ratio
quadrat
rotationorthogon
combin
design
valid
optim
combin
sever
method
compat
studi
tube
serial
dilut
method
agar
checkerboard
dilut
method
among
method
checkerboard
evidencebas
complementari
altern
medicin
microdilut
one
commonli
use
assay
twocompon
combin
quickli
screen
antimicrobi
activ
detect
sensit
method
could
much
improv
ad
fluoresc
dye
resazurin
make
accur
method
determin
antimrsa
activ
ba
howev
checkerboard
microdilut
suitabl
investig
multicompon
combin
henc
quadrat
rotationorthogon
combin
design
qrcd
adopt
seek
optim
combin
compar
unifactor
experi
orthogon
design
qrcd
basic
retain
advantag
less
experi
simpl
calcul
absenc
correl
regress
coeffici
addit
optim
region
concentr
could
directli
obtain
studi
help
clarifi
interact
among
ba
provid
new
idea
exploit
multicompon
drug
rhizoma
coptidi
phellodendri
chinensi
berberidi
radix
collect
place
product
berberin
ber
lot
palmatin
pal
lot
puriti
provid
nation
institut
food
drug
control
jatrorrhizin
jat
coptisin
cop
epiberberin
epi
puriti
purchas
zelang
medic
technolog
co
ltd
nanj
china
structur
given
figur
chemic
use
analyt
grade
avail
local
cultur
mrsa
srain
escherichia
coli
e
coli
cctcc
staphylococcu
aureu
aureu
cctcc
shigella
dysenteria
dysenteria
cctcc
streptococcu
pneumonia
pneumonia
candida
albican
c
albican
cctcc
provid
china
center
type
cultur
collect
cultiv
microbiolog
laboratori
militari
hospit
china
beij
china
briefli
broth
cultur
medium
contain
g
pepton
g
beef
extract
g
nacl
dissolv
ml
deioniz
water
ph
cultur
medium
steril
highpressur
steam
mpa
c
min
initi
strain
inocul
ml
broth
cultur
medium
ml
widemouth
glass
bottl
incub
shaker
h
c
rotat
speed
incub
shaker
rpm
flask
envelop
cotton
plug
enough
oxygen
use
strain
experi
bacteria
transform
grown
cationadjust
mueller
hinton
broth
camhb
prepar
g
casein
acid
hydrolys
g
beef
extract
g
starch
dissolv
ml
distil
water
final
ph
c
cultur
medium
steril
highpressur
steam
mpa
c
min
store
refriger
c
antimrsa
activ
ba
determin
broth
microdilut
palmatin
coptisin
jatrorrhizin
epiberberin
accord
modifi
version
clinic
laboratori
standard
institut
clsi
protocol
includ
fluoresc
determin
use
resazurin
resazurin
blue
dye
nonfluoresc
reduc
pink
color
highli
red
fluoresc
resorufin
larg
chang
perceiv
color
hue
thick
concentr
observ
sampl
increas
decreas
fluoresc
intens
differ
growth
stage
bacteria
determin
synergi
hybrid
multimod
micropl
reader
biotek
winooski
usa
concentr
resazurin
sodium
salt
sigma
saint
loui
mo
usa
assay
gml
excit
emiss
wavelength
set
nm
nm
respect
fluoresc
intens
determin
h
experi
fluoresc
intens
peak
concentr
extract
ba
gml
row
respect
row
set
infect
control
contain
bacteria
extract
noninfect
medium
control
contain
neither
extract
bacteria
follow
fluorometr
measur
effect
concentr
ec
calcul
use
fluoresc
intens
row
infect
control
assay
checkerboard
assay
adopt
assay
possibl
twocompon
combin
activ
compound
test
duplic
dose
matric
six
dose
compound
repres
data
point
effect
prolifer
mrsa
five
test
concentr
compound
chosen
first
determin
ec
compound
singl
agent
assay
evidencebas
complementari
altern
medicin
select
higher
lower
concentr
studi
perform
figur
combin
score
identifi
antibacteri
effect
greater
effect
individu
compon
use
resazurin
prolifer
assay
combin
calcul
differ
observ
effect
combin
dose
predict
effect
base
two
model
additiv
highest
singl
agent
hsa
model
larger
effect
produc
combin
singl
agent
concentr
mixtur
contrast
bliss
additiv
model
predict
combin
respons
c
two
singl
compound
effect
b
c
effect
express
fraction
inhibit
effectbas
synergi
model
make
assumpt
function
form
doserespons
curv
requir
doserespons
inform
lie
outsid
rang
sampl
screen
matrix
determin
whether
readout
combin
therapi
addit
synergist
indiffer
calcul
fraction
inhibitori
concentr
indic
fici
checkerboard
assay
fici
repres
sum
fic
drug
test
fic
determin
drug
divid
mic
drug
use
combin
mic
drug
use
alon
qrcd
adopt
investig
multicompon
combin
ba
studi
compon
set
factor
factor
contain
level
gml
interv
gml
code
factor
level
tabl
design
experiment
design
combin
inhibit
ratio
calcul
determin
fluoresc
combin
test
regress
equat
establish
upon
principl
drug
combin
optim
combin
could
obtain
use
data
process
system
dp
infect
mice
render
neutropen
ip
inject
ba
daili
consecut
day
dosag
mgkg
bodi
weight
inocul
mice
infect
ml
inoculum
mrsa
cfuml
warm
salin
c
later
tail
vein
day
pretreat
ba
group
mice
inject
ml
cfuml
dead
mrsa
suspens
per
mous
neg
control
addit
group
mice
inocul
ml
cfuml
suspens
per
mous
without
advanc
ba
treatment
neg
control
confirm
infect
determin
duplic
final
isol
candid
data
averag
three
experi
group
mice
observ
day
infect
end
point
surviv
mice
kill
co
exposur
differ
tissu
mice
die
observ
period
kill
survivor
remov
asept
condit
subject
detail
necropsi
examin
kidney
lung
brain
mice
homogen
steril
salin
serial
dilut
homogen
plate
onto
sabouraud
dextros
agar
calcul
cfu
h
incub
c
analys
data
obtain
qrcd
analyz
use
anova
lack
fit
test
regress
equat
analyz
use
dp
dp
chang
bacteri
densiti
tissu
express
chang
log
cfu
treat
untreat
anim
report
use
descript
statist
effect
combin
undertaken
appropri
statist
test
mean
surviv
time
mst
data
group
treat
mice
compar
untreat
control
use
oneway
anova
student
ttest
use
signific
level
defin
determin
activ
singl
alkaloid
mrsa
strain
contain
meca
gene
nora
gene
absenc
drug
intervent
fluoresc
absorpt
reach
around
hour
incub
contrast
fluoresc
intens
inhibit
ad
posit
control
cefoxitin
alkaloid
inhibit
effect
could
calcul
follow
equat
repres
inhibit
ratio
repres
fluoresc
absorpt
neg
control
row
repres
fluoresc
absorpt
alkaloid
group
row
ec
valu
calcul
iconcentr
curv
result
show
among
alkaloid
berberin
show
strongest
antimicrobi
activ
figur
inhibit
ratio
reach
concentr
gml
gml
respect
sequenc
activ
alkaloid
ber
cop
jat
pal
epi
test
adopt
resazurin
fluoresc
determin
could
found
figur
method
reliabl
ad
cefoxitin
ber
color
mrsa
suspens
chang
regularli
increas
concentr
figur
b
fluoresc
intens
h
significantli
decreas
ad
gml
cefoxitin
figur
b
f
addit
show
densiti
mrsa
increas
significantli
incub
h
figur
c
howev
coloni
count
significantli
decreas
ad
gml
cefoxitin
gml
ber
figur
g
h
date
report
drug
combin
mrsa
tannin
polyphenol
baicalein
ciprofloxacin
flavon
lactam
antibiot
usnic
acid
antimicrobi
agent
anacard
acid
methicillin
arbekacin
vancomycin
polyoxometal
oxacillin
fosfomycin
arbekacin
gemcitabin
gentamicin
penicillin
salix
babylonica
l
ciprofloxacin
isati
tinctoria
l
ceftriaxon
scutellaria
baicalensi
g
rosmarinu
officinali
cefuroxim
pannarin
antibiot
howev
knowledg
report
combin
ingredi
tradit
medicin
present
studi
show
alkaloid
antimrsa
activ
activ
rel
weak
compar
antibiot
reason
might
bacteria
multipl
drug
resist
result
low
absolut
concentr
insid
cell
membran
bacteria
evolv
numer
defens
antimicrobi
agent
drugresist
pathogen
rise
gener
effect
defens
confer
ubiquit
multidrug
resist
pump
mdr
membran
translocas
extrud
structur
unrel
toxin
cell
ms
regressionm
error
indic
signific
therefor
regress
result
reliabl
regress
coeffici
test
signific
item
signific
elimin
level
equat
optim
analyz
dp
program
number
higher
meanwhil
weight
mean
confid
interv
calcul
tabl
standard
weight
mean
berberin
weight
mean
alkaloid
obtain
optim
ratio
obtain
follow
multipl
design
method
central
composit
design
boxbehnken
design
doptim
design
compar
method
qrcd
present
two
featur
sacrific
partial
orthogon
obtain
rotat
retain
merit
less
test
time
simpl
calcul
low
depend
among
regress
coeffici
discard
disadvantag
lack
rotat
screen
optim
region
predict
valu
result
section
consist
result
figur
show
optim
combin
strongest
inhibit
effect
e
coli
aureu
dysenteria
pneumonia
specif
ec
geometr
proport
alkaloid
e
coli
time
larger
optim
combin
ec
berberidi
radix
aureu
time
larger
optim
combin
ec
geometr
proport
alkaloid
dysenteria
time
larger
optim
combin
ec
berberidi
radix
pneumonia
time
larger
optim
combin
addit
antimicrobi
activ
optim
combin
c
albican
rank
second
rhizoma
coptidi
result
indic
optim
combin
applic
also
laboratori
strain
studi
provid
fast
reliabl
way
interact
research
chemic
also
laid
foundat
develop
applic
multicompon
drug
howev
studi
involv
vitro
test
spread
onto
sabouraud
dextros
agar
plate
coloni
count
determin
h
c
calcul
geometr
mean
compar
efficaci
assess
chang
bacteri
densiti
kidney
lung
brain
tissu
infect
mice
treatment
percent
surviv
mst
undertaken
test
compound
result
obtain
figur
show
combin
phellodendri
chinensi
cortex
geometr
proport
alkaloid
group
signific
therapeut
effect
bodi
weight
percent
surviv
infect
mice
compar
placebo
control
cours
infect
indic
mst
placebo
control
geometr
proport
alkaloid
group
combin
phellodendri
chinensi
cortex
group
respect
contrari
combin
rhizoma
coptidi
cefoxitin
optim
combin
studi
group
show
signific
therapeut
effect
optim
combin
studi
group
show
strongest
antimrsa
activ
vivo
mst
optim
combin
group
infect
mrsa
bodi
weight
reduc
compar
placebo
control
hair
becam
spars
figur
b
count
bacteri
coloni
indic
remain
bacteria
determin
kidney
lung
brain
tissu
among
combin
cefoxitin
combin
rhizoma
coptidi
optim
combin
studi
significantli
reduc
log
cfu
cellg
compar
placebo
control
optim
combin
remain
bacteria
log
cfu
cellg
kidney
lung
brain
reduc
dramat
respect
figur
g
summari
studi
initi
investig
antimrsa
activ
singl
berberin
alkaloid
mrsa
individu
ec
obtain
thereaft
higher
lower
concentr
ec
chosen
interact
among
berberin
alkaloid
checkerboard
assay
synerget
antagonist
interact
clarifi
next
multicompon
combin
studi
qrcd
optim
combin
antimrsa
activ
screen
addit
optim
combin
appli
potenc
type
strain
demonstr
combin
wide
versatil
furthermor
ba
test
cyimmunocompromis
mous
model
valid
therapeut
effect
select
combin
e
optim
combin
studi
group
f
geometr
proport
alkaloid
group
g
neg
group
noninfect
mice
without
given
drug
h
placebo
control
